@.516698: #صنعاء_تعز_عدن_اب_ذمار_حجة_حضرموت #صنعاء_تعز_عدن_اب_ذمار_حجة_حضرموت #السعودية🇸🇦

فتــى𓄹خولان 𓄼𓅗
فتــى𓄹خولان 𓄼𓅗
Open In TikTok:
Region: JO
Tuesday 01 September 2026 19:51:56 GMT
25175
1761
126
153

Music

Download

Comments

.516698
فتــى𓄹خولان 𓄼𓅗 :
سلام ربي عليك ♥
2026-09-02 19:30:52
7
user570138247878
صقرشرف الظرمه :
هاولإ الرجال الصادقين المؤمنين المناظلين
2026-09-01 22:46:39
35
nizar.albadani
𝑁𝑖𝑧𝑎𝑟 𝐴𝑙-𝐵𝑎𝑑𝑎𝑛𝑖 :
وين هذا المقطع من زمان يسعد دينك
2026-09-02 07:46:18
10
user1739366988150
فتى عمران :
هذا الشهيد البطل الشجاع اصاطق
2026-09-02 17:35:57
2
suhail.star6
Suhail star :
ولا حاجه بس دخلت ادور على البنت اللي تريد تتزوج واحد فقير
2026-09-02 19:19:00
1
user4767610990337
ذيِّبً أّلَخِـلَأّأّأّأّ؛ :
سلام ربي عليه الحر ابن الحر
2026-09-02 02:24:10
7
krar.alhmiary
Krar AL-hmiary :
انا أفدالك يامؤمن
2026-09-02 12:02:18
4
user333287792628391
محمد :
والله انك رجال وبن رجال وفخر المه السلميه وخسرتن بك خسره كبيره
2026-09-02 18:54:19
1
user86157699140140
الماربي :
ياخوي فك اتنزيل
2026-09-02 16:44:16
1
user7109574737152
بن خولان مخاوي اليل :
سلام ربي عليك 💯🫡🫡🫡
2026-09-02 00:26:21
4
muradhadi8
murad hadi :
ازكى السلااااااااااام
2026-09-02 09:17:42
1
user3508698613587
user3508698613587 :
أذا سلم الدين صلحت الحيه هاولا الرجال امتلا قلوبهم ايمان ورشد سلام ربي عليهم
2026-09-02 17:08:09
1
abdusalam.alghary
Abdusalam Alghary Alghary :
سلام سلام الله عليه
2026-09-02 09:33:38
1
user1811915681422
عبدالملك مزلم :
هولا شجعان
2026-09-02 07:42:06
1
zaidtalbi5
زيد الطالبي :
لله درك👍🥰
2026-09-02 00:18:45
3
user7448366197116
user66913646303 :
الله الله
2026-09-02 03:00:59
3
user4837077284083
ابو مالك عرو :
رحمه الله تغشاه
2026-09-02 06:17:39
1
user7531979878770
آبًنِ آليمـہنـ آصــل آلعـہربـ :
آلَتُذِكيّر .......... هِآذِآ. آلَشّـهِيّدُ. آلَبّـطٌلَ. تُوِفُيّقَ. طٌنِيّنِهِ ...... آلَرآزَحًيّ.. سًسًـلَآمِ. ربّـيّ. عَـلَآ. روِحًـهِ. آلَطٌآهِرهِ 🥺
2026-09-02 18:32:34
4
user6729732949830
😇 :
رحمة الله عليك
2026-09-02 05:08:49
1
user7203333705206
ابو مهدي العمري :
هلا والله ومليون مرحبا
2026-09-02 18:22:03
1
zggg711
ّ :
سلام ربي عليه
2026-09-02 18:32:38
1
user19661925461057
ℋ𝒜ℳ𝒜𝒟 :
سلام الله على روحك الطاهره يا توفيق سلام الله عليه
2026-09-02 11:25:54
2
user7546961700110
#حساب ديني # :
لله درك أنا اشهد انك حر ابن حر
2026-09-02 17:08:13
2
user2434637549615
عبد الملك الشوذبي :
سلام الله على روحك الطاهره لاكن التصميم ماله داعي
2026-09-02 17:42:29
2
To see more videos from user @.516698, please go to the Tikwm homepage.

Other Videos

Survodutide might be WAY more interesting than just another weight-loss drug. 🧬🔥 Everyone is watching the scale. I’m watching the liver. Survodutide is an investigational dual GLP-1 + glucagon receptor agonist and the Phase 3 data are getting seriously interesting. In people with obesity and at-risk fatty liver disease (MASLD), 84.2% of participants receiving survodutide achieved at least a 30% reduction in liver fat at 48 weeks versus 24.3% with placebo. Even crazier? About 6 out of 10 reached liver fat levels below 5%.  And in the separate obesity trial, survodutide produced up to 16.6% average weight loss over 76 weeks.  But here’s what fascinates me. Survodutide isn’t simply making people eat less. We’re manipulating the same brain-gut-metabolic signaling network involved in hunger, satiety, energy balance and metabolic regulation. Preclinical research published this year showed survodutide activating brain regions involved in appetite regulation through its GLP-1 activity.  So maybe the bigger conversation isn’t: “How much weight can this drug make someone lose?” Maybe it’s: “Why was the metabolic system dysregulated enough to produce obesity and fatty liver in the first place?” The drugs are getting better. Now our understanding of the biology needs to get better too. 🔬 Educational purposes only. Not medical advice. Survodutide remains investigational, and these results should not be interpreted as establishing it as an approved treatment. #Survodutide #GLP1 #Glucagon #WeightLoss #Obesity
Survodutide might be WAY more interesting than just another weight-loss drug. 🧬🔥 Everyone is watching the scale. I’m watching the liver. Survodutide is an investigational dual GLP-1 + glucagon receptor agonist and the Phase 3 data are getting seriously interesting. In people with obesity and at-risk fatty liver disease (MASLD), 84.2% of participants receiving survodutide achieved at least a 30% reduction in liver fat at 48 weeks versus 24.3% with placebo. Even crazier? About 6 out of 10 reached liver fat levels below 5%. And in the separate obesity trial, survodutide produced up to 16.6% average weight loss over 76 weeks. But here’s what fascinates me. Survodutide isn’t simply making people eat less. We’re manipulating the same brain-gut-metabolic signaling network involved in hunger, satiety, energy balance and metabolic regulation. Preclinical research published this year showed survodutide activating brain regions involved in appetite regulation through its GLP-1 activity. So maybe the bigger conversation isn’t: “How much weight can this drug make someone lose?” Maybe it’s: “Why was the metabolic system dysregulated enough to produce obesity and fatty liver in the first place?” The drugs are getting better. Now our understanding of the biology needs to get better too. 🔬 Educational purposes only. Not medical advice. Survodutide remains investigational, and these results should not be interpreted as establishing it as an approved treatment. #Survodutide #GLP1 #Glucagon #WeightLoss #Obesity

About